Treatment Information

Back

Ovarian Cancer treatment details. Chemotherapy, Biologic therapy.

Indiana University, Indianapolis, IN, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Indianapolis, IN
Treatments:Chemotherapy, Biologic therapyHospital:Indiana University
Drugs:Journal:Link
Date:Dec 2011

Description:

Patients:
This phase II study involved 14 women with ovarian cancer or primary peritoneal carcinomatosis who had received prior platinum-based chemotherapy. The median patient age was 52.5 years.

Treatment:
Patients were treated with the chemotherapy agent topotecan and the biologic therapy agent sorafenib, which blocks cancer cell growth by targeting tyrosine kinase proteins on the cell surface.

Toxicities:
The most severe toxicities were of grade 4 and included leukopenia/neutropenia, thrombocytopenia, infection and fatigue. Grade 3 nausea, diarrhea/constipation, and pain were also reported.

Results:
The median overall survival was 14 months.

Support:
The sorafenib drug was provided by Bayer.

Correspondence: Dr. D. Matei; email: [email protected]



Back